Mark Noller
Urology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 24
- 7 carriers
- Office
- 1
Offices
1 location · El Camino Health Medical Network LLC · 202 clinicians in this group
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
24 plans · 7 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Mark Noller’s office at (408) 871-5220 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
24 of 24 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence C54669 · Current
Licensed to practise in California · since 2011 · expires 2028-07-31 · Saint Louis University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$267,202
Medicare paid this office $267,202 for 482 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 418 | $101,778 | $114 |
| Detection test by nucleic acid for organism, amplified probe technique | 50 | $22,834 | $34 |
| Detection test by nucleic acid for multiple organisms, amplified probe(s) technique | 50 | $16,771 | $69 |
| New patient visit (45+ min) | 92 | $12,796 | $139 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 11 | $9,410 | None |
See all 29 services
| Return visit (30+ min) | 418 | $101,778 | $114 |
| Detection test by nucleic acid for organism, amplified probe technique | 50 | $22,834 | $34 |
| Detection test by nucleic acid for multiple organisms, amplified probe(s) technique | 50 | $16,771 | $69 |
| New patient visit (45+ min) | 92 | $12,796 | $139 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 11 | $9,410 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 29 | $8,229 | $242 |
| Short return visit (20+ min) | 70 | $7,478 | $80 |
| Ultrasound measurement of bladder capacity after voiding | 305 | $5,895 | $12 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 254 | $5,875 | $15 |
| Biopsy of prostate gland | 19 | $4,443 | $234 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 12 | $4,383 | $365 |
| Ultrasound scan of pelvic region through rectum | 25 | $3,719 | $149 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 11 | $3,113 | $283 |
| Detection test for candida species (yeast), amplified probe technique | 51 | $2,889 | $34 |
| Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique | 51 | $2,889 | $34 |
| Detection test by nucleic acid for trichomonas vaginalis (genital parasite), amplified probe technique | 50 | $2,854 | $34 |
| Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | 50 | $2,854 | $34 |
| Detection test by nucleic acid for chlamydia trachomatis, amplified probe technique | 50 | $2,854 | $34 |
| Detection of mycoplasma genitalium by dna or rna probe | 50 | $2,854 | $34 |
| Detection test by nucleic acid for neisseria gonorrhoeae (gonorrhoeae bacteria), amplified probe technique | 50 | $2,854 | $34 |
| Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | 50 | $2,854 | $34 |
| Detection test by nucleic acid for staphylococcus aureus, methicillin resistant (mrsa bacteria), amplified probe technique | 50 | $2,854 | $34 |
| Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique | 50 | $2,854 | $34 |
| Urinalysis, manual test | 385 | $2,453 | $3 |
| Long return visit (40+ min) | 13 | $2,181 | $168 |
| Complete ultrasound scan behind abdominal cavity | 18 | $2,051 | $114 |
| Complete ultrasound scan of pelvis | 17 | $1,721 | $101 |
| Detection test for gardnerella vaginalis (bacteria), amplified probe technique | 26 | $1,685 | $34 |
| Manual urinalysis test with examination using microscope, non-automated | 126 | $599 | $4 |
Procedures Medicare counted
| Prostate resection | 1-10 | None |
| Removal of skin lesions | 1-10 | None |
Who their Medicare patients are
482 Original Medicare patients in 2024. Average age 78 · Women 20% · Also on Medicaid 3% · Health risk score 1.05. At or below the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 75% · Coronary heart disease 40% · Diabetes 35% · Cancer 25% · Atrial fibrillation 24% · Chronic kidney disease 23% · Heart failure 16% · COPD 11% · Stroke 11% · Depression 9% · Dementia 7%.
The office billed $953,004, Medicare allowed $330,814 and paid $267,202; for 4,987 services of 77 kinds; $9,410 of it was for drugs given in the office and $257,792 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 482 | 4,987 | 78 | 1.05 | $953,004 | $267,202 |
| 2023 | 459 | 5,950 | 78 | 1.13 | $741,744 | $330,500 |
| 2022 | 474 | 2,939 | 77 | 1.15 | $553,787 | $223,653 |
| 2021 | 477 | 2,953 | 77 | 1.10 | $583,239 | $232,894 |
| 2020 | 461 | 2,546 | 77 | 1.21 | $503,794 | $182,801 |
| 2019 | 512 | 3,012 | 76 | 1.22 | $627,320 | $225,600 |
| 2018 | 505 | 3,752 | 76 | 1.15 | $651,153 | $224,394 |
| 2017 | 458 | 2,841 | 76 | 1.23 | $594,613 | $205,362 |
| 2016 | 432 | 2,396 | 76 | 1.31 | $542,318 | $182,125 |
| 2015 | 392 | 2,610 | 76 | 1.49 | $518,005 | $180,887 |
| 2014 | 476 | 3,457 | 77 | 1.31 | $687,623 | $237,843 |
| 2013 | 381 | 2,419 | 77 | 1.45 | $473,695 | $164,694 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 23 services
| Return visit (30+ min) | 403 | $104,597 | $110 |
| Detection test by nucleic acid for organism, amplified probe technique | 84 | $42,539 | $34 |
| Detection test by nucleic acid for multiple organisms, amplified probe(s) technique | 83 | $31,076 | $69 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 14 | $13,383 | None |
| New patient visit (45+ min) | 88 | $12,739 | $145 |
| Diagnostic exam of bladder and urethra using an endoscope | 46 | $12,250 | $250 |
| Short return visit (20+ min) | 82 | $9,223 | $82 |
| Complicated removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 13 | $6,059 | $466 |
| Detection test for candida species (yeast), amplified probe technique | 84 | $5,296 | $34 |
| Detection test by nucleic acid for chlamydia trachomatis, amplified probe technique | 84 | $5,296 | $34 |
| Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique | 84 | $5,296 | $34 |
| Detection test by nucleic acid for neisseria gonorrhoeae (gonorrhoeae bacteria), amplified probe technique | 84 | $5,296 | $34 |
| Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | 84 | $5,296 | $34 |
| Detection test by nucleic acid for staphylococcus aureus, methicillin resistant (mrsa bacteria), amplified probe technique | 84 | $5,296 | $34 |
| Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique | 84 | $5,296 | $34 |
| Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | 84 | $5,296 | $34 |
| Detection test by nucleic acid for trichomonas vaginalis (genital parasite), amplified probe technique | 84 | $5,296 | $34 |
| Detection of mycoplasma genitalium by dna or rna probe | 81 | $5,124 | $34 |
| Manual urinalysis test with examination using microscope, non-automated | 396 | $3,392 | $4 |
| Detection test for gardnerella vaginalis (bacteria), amplified probe technique | 37 | $2,786 | $34 |
| Ultrasound measurement of bladder capacity after voiding | 135 | $2,261 | $11 |
| Removal or manipulation of stone in ureter or kidney using an endoscope | 13 | $1,025 | $79 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $629 | $33 |
2022: 12 services
| Return visit (30+ min) | 416 | $122,713 | $112 |
| New patient visit (45+ min) | 135 | $20,122 | $149 |
| Complicated insertion of bladder tube | 19 | $13,975 | $152 |
| Diagnostic exam of bladder and urethra using an endoscope | 32 | $9,021 | $258 |
| Complicated removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 12 | $5,691 | $474 |
| Crushing of stone of ureter using an endoscope | 12 | $4,251 | $354 |
| Ultrasound measurement of bladder capacity after voiding | 226 | $3,648 | $11 |
| Manual urinalysis test with examination using microscope, non-automated | 417 | $3,364 | $4 |
| Biopsy of prostate gland | 12 | $2,953 | $246 |
| Long return visit (40+ min) | 11 | $1,895 | $172 |
| Insertion of stent in ureter using an endoscope | 14 | $1,452 | $91 |
| Removal or manipulation of stone in ureter or kidney using an endoscope | 11 | $513 | $47 |
2021: 13 services
| Return visit (30+ min) | 421 | $128,884 | $117 |
| New patient visit (45+ min) | 108 | $16,213 | $150 |
| Diagnostic exam of bladder and urethra using an endoscope | 55 | $14,870 | $244 |
| Complicated insertion of bladder tube | 14 | $10,017 | $152 |
| Complicated removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 17 | $8,675 | $482 |
| Ultrasound measurement of bladder capacity after voiding | 259 | $5,063 | $11 |
| Manual urinalysis test with examination using microscope, non-automated | 398 | $3,209 | $4 |
| Biopsy of prostate gland | 11 | $2,818 | $256 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,380 | $183 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 17 | $1,681 | $35 |
| Insertion of stent in ureter using an endoscope | 13 | $1,290 | $99 |
| Short return visit (20+ min) | 14 | $1,158 | $83 |
| Ultrasonic guidance for needle placement | 11 | $644 | $59 |
2020: 14 services
| Return visit (30+ min) | 383 | $85,672 | $99 |
| New patient visit (45+ min) | 103 | $14,948 | $145 |
| Diagnostic exam of bladder and urethra using an endoscope | 58 | $13,639 | $210 |
| Complicated insertion of bladder tube | 13 | $8,737 | $139 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $5,369 | $185 |
| Complicated removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 11 | $5,098 | $463 |
| Ultrasound measurement of bladder capacity after voiding | 188 | $3,268 | $11 |
| Manual urinalysis test with examination using microscope, non-automated | 382 | $3,019 | $4 |
| Complete ultrasound scan behind abdominal cavity | 25 | $2,847 | $114 |
| Complete ultrasound scan of pelvis | 25 | $2,743 | $110 |
| Short return visit (20+ min) | 27 | $2,232 | $66 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 22 | $1,935 | $36 |
| Long return visit (40+ min) | 13 | $1,824 | $140 |
| Imaging of urinary tract following injection of a contrast agent | 12 | $306 | $24 |
2019: 15 services
| Return visit (30+ min) | 431 | $94,877 | $98 |
| New patient visit (45+ min) | 141 | $21,064 | $149 |
| Diagnostic exam of bladder and urethra using an endoscope | 95 | $19,970 | $188 |
| Complicated insertion of bladder tube | 13 | $9,227 | $130 |
| Complicated removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 18 | $7,594 | $422 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 19 | $6,770 | $356 |
| Complete ultrasound scan of pelvis | 36 | $4,080 | $113 |
| Complete ultrasound scan behind abdominal cavity | 35 | $4,032 | $115 |
| Manual urinalysis test with examination using microscope, non-automated | 442 | $3,694 | $4 |
| Ultrasound measurement of bladder capacity after voiding | 174 | $3,613 | $13 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,475 | $174 |
| Biopsy of prostate gland | 13 | $3,140 | $242 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 17 | $2,808 | $36 |
| Removal or manipulation of stone in ureter or kidney using an endoscope | 20 | $1,253 | $63 |
| Imaging of urinary tract following injection of a contrast agent | 11 | $261 | $24 |
2018: 18 services
| Return visit (30+ min) | 412 | $93,244 | $95 |
| New patient visit (45+ min) | 148 | $21,484 | $145 |
| Diagnostic exam of bladder and urethra using an endoscope | 84 | $15,277 | $161 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 11 | $14,756 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $6,731 | $182 |
| Short return visit (20+ min) | 51 | $5,318 | $63 |
| Complete ultrasound scan behind abdominal cavity | 37 | $4,423 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $4,213 | $94 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 11 | $4,141 | $376 |
| Ultrasound measurement of bladder capacity after voiding | 158 | $4,128 | $16 |
| Manual urinalysis test with examination using microscope, non-automated | 432 | $3,813 | $4 |
| Complete ultrasound scan of pelvis | 34 | $3,741 | $110 |
| Biopsy of prostate gland | 16 | $3,408 | $213 |
| Ultrasound scan of pelvic region through rectum | 18 | $1,532 | $85 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $946 | $31 |
| Ultrasonic guidance for needle placement | 16 | $870 | $54 |
| Removal or manipulation of stone in ureter or kidney using an endoscope | 11 | $490 | $45 |
| Imaging of urinary tract following injection of a contrast agent | 12 | $193 | $16 |
2017: 17 services
| Return visit (30+ min) | 361 | $82,918 | $96 |
| New patient visit (45+ min) | 163 | $24,055 | $148 |
| Diagnostic exam of bladder and urethra using an endoscope | 84 | $15,355 | $157 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 12 | $13,823 | None |
| Short return visit (20+ min) | 63 | $7,710 | $67 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $4,895 | $181 |
| Manual urinalysis test with examination using microscope, non-automated | 393 | $3,815 | $4 |
| Complete ultrasound scan behind abdominal cavity | 33 | $3,813 | $116 |
| Complete ultrasound scan of pelvis | 34 | $3,753 | $110 |
| Biopsy of prostate gland | 14 | $3,392 | $242 |
| Ultrasound measurement of bladder capacity after voiding | 106 | $3,137 | $20 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 20 | $2,131 | $35 |
| Ultrasound scan of pelvic region through rectum | 14 | $1,354 | $97 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $1,222 | $32 |
| Ultrasonic guidance for needle placement | 14 | $884 | $59 |
| Imaging of urinary tract following injection of a contrast agent | 12 | $225 | $16 |
| Electronic assessment of bladder emptying | 13 | $191 | $15 |
2016: 16 services
| Return visit (30+ min) | 327 | $69,449 | $91 |
| Diagnostic exam of bladder and urethra using an endoscope | 95 | $19,208 | $183 |
| New patient visit (45+ min) | 131 | $18,045 | $138 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $6,405 | $173 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 13 | $5,537 | $369 |
| Short return visit (20+ min) | 41 | $5,247 | $63 |
| Complete ultrasound scan behind abdominal cavity | 41 | $4,437 | $108 |
| Complicated removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 11 | $4,126 | $375 |
| Complete ultrasound scan of pelvis | 40 | $3,219 | $80 |
| Manual urinalysis test with examination using microscope, non-automated | 348 | $3,039 | $4 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 30 | $2,814 | $34 |
| Ultrasound measurement of bladder capacity after voiding | 77 | $1,873 | $19 |
| Long return visit (40+ min) | 15 | $1,684 | $112 |
| Ultrasound scan of pelvic region through rectum | 11 | $1,001 | $91 |
| Removal or manipulation of stone in ureter or kidney using an endoscope | 13 | $616 | $44 |
| Imaging of urinary tract following injection of a contrast agent | 16 | $292 | $15 |
2015: 19 services
| Return visit (30+ min) | 258 | $58,346 | $94 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 74 | $18,915 | $34 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 16 | $12,907 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 62 | $11,685 | $177 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 12 | $8,965 | $747 |
| New patient visit (45+ min) | 65 | $8,946 | $138 |
| Short return visit (20+ min) | 45 | $6,439 | $64 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 17 | $6,325 | $351 |
| Diagnostic exam of bladder and urethra using an endoscope | 27 | $6,034 | $195 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 14 | $3,216 | $230 |
| Manual urinalysis test with examination using microscope, non-automated | 285 | $2,835 | $4 |
| Long return visit (40+ min) | 14 | $2,038 | $127 |
| Ultrasound measurement of bladder capacity after voiding | 67 | $1,596 | $19 |
| Insertion of stent in ureter using an endoscope | 11 | $1,544 | $119 |
| New patient visit (30+ min) | 14 | $1,401 | $100 |
| Cell examination of specimen, selective cellular enhancement technique | 30 | $1,131 | $35 |
| Removal or manipulation of stone in ureter or kidney using an endoscope | 18 | $1,117 | $59 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $959 | $31 |
| Imaging of urinary tract following injection of a contrast agent | 25 | $464 | $16 |
2014: 24 services
| Short return visit (20+ min) | 272 | $37,894 | $64 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 95 | $23,584 | $34 |
| Return visit (30+ min) | 151 | $21,193 | $99 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 22 | $20,951 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 88 | $16,216 | $178 |
| New patient visit (45+ min) | 101 | $13,980 | $138 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 37 | $9,681 | $225 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 21 | $9,583 | $369 |
| Biopsy of bladder using an endoscope | 19 | $7,353 | $350 |
| Dilation of urethra using an endoscope | 24 | $6,670 | $247 |
| Ultrasound measurement of bladder capacity after voiding | 131 | $3,301 | $19 |
| Manual urinalysis test with examination using microscope, non-automated | 357 | $3,259 | $4 |
| Long return visit (40+ min) | 21 | $2,686 | $128 |
| Diagnostic exam of bladder and urethra using an endoscope | 17 | $2,662 | $157 |
| New patient visit (30+ min) | 19 | $1,805 | $95 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 22 | $1,564 | $32 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $1,386 | $92 |
| Insertion of stent in ureter using an endoscope | 16 | $1,335 | $83 |
| Removal or manipulation of stone in ureter or kidney using an endoscope | 21 | $1,243 | $50 |
| Limited ultrasound scan behind abdominal cavity | 15 | $851 | $57 |
| Imaging of urinary tract following injection of a contrast agent | 31 | $569 | $16 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $222 | $19 |
| Electronic assessment of bladder emptying | 11 | $149 | $14 |
| Urinalysis, manual test | 20 | $75 | $3 |
2013: 14 services
| Short return visit (20+ min) | 195 | $33,233 | $66 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 90 | $19,413 | $34 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 95 | $17,850 | $175 |
| New patient visit (45+ min) | 107 | $15,166 | $142 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 29 | $8,055 | $218 |
| Biopsy of bladder using an endoscope | 18 | $7,935 | $361 |
| Crushing of stone of ureter using an endoscope | 12 | $4,340 | $362 |
| Insertion of stent in ureter using an endoscope | 22 | $2,885 | $111 |
| Return visit (30+ min) | 25 | $2,485 | $92 |
| Long return visit (40+ min) | 18 | $2,340 | $130 |
| Manual urinalysis test with examination using microscope, non-automated | 234 | $2,218 | $4 |
| Ultrasound measurement of bladder capacity after voiding | 75 | $2,013 | $20 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 42 | $1,041 | $19 |
| Removal or manipulation of stone in ureter or kidney using an endoscope | 12 | $584 | $49 |
Drugs they prescribed that Part D paid
$327,987
Pharmacies billed $327,987 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (28 of 1,661) in 2024. At or below the middle of the specialty; the typical urology clinician is at 2%.
1,491 generic and fewer than 11 brand-name prescriptions · $327,987 in drug cost · 237 antibiotic prescriptions to 140 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xtandi | 15 | $182,534 | $12,169 |
| Gemtesa | 74 | $59,112 | $799 |
| Myrbetriq | 66 | $43,175 | $654 |
| Tamsulosin | 410 | $7,879 | $19 |
| Finasteride | 291 | $5,593 | $19 |
See all 24 drugs
| Xtandi | 15 | $182,534 | $12,169 |
| Gemtesa | 74 | $59,112 | $799 |
| Myrbetriq | 66 | $43,175 | $654 |
| Tamsulosin | 410 | $7,879 | $19 |
| Finasteride | 291 | $5,593 | $19 |
| Dutasteride | 146 | $5,357 | $37 |
| Silodosin | 59 | $5,177 | $88 |
| Potassium Citrate Er | 26 | $2,434 | $94 |
| Testosterone | 19 | $2,261 | $119 |
| Bicalutamide | 32 | $1,324 | $41 |
| Oxybutynin Chloride Er | 45 | $1,219 | $27 |
| Tolterodine Tartrate Er | 11 | $1,037 | $94 |
| Ciprofloxacin | 116 | $682 | $6 |
| Alfuzosin Hcl Er | 24 | $641 | $27 |
| Nitrofurantoin Mono-Macro | 20 | $457 | $23 |
| Cefdinir | 16 | $355 | $22 |
| Clobetasol Propionate | 11 | $209 | $19 |
| Pentoxifylline | 13 | $192 | $15 |
| Sulfamethoxazole-Trimethoprim | 30 | $177 | $6 |
| Cephalexin | 26 | $173 | $7 |
| Hydrocodone-Acetaminophen | 23 | $166 | $7 |
| Amoxicillin-Clavulanate Potass | 13 | $127 | $10 |
| Allopurinol | 27 | $91 | $3 |
| Sildenafil Citrate | 13 | $58 | $4 |
Year by year
| 2024 | 1,661 | 406 | 2% (28) | None | $327,987 |
| 2023 | 1,706 | 376 | 2% (28) | 10% | $340,032 |
| 2022 | 1,690 | 363 | 2% (25) | None | $285,403 |
| 2021 | 1,623 | 359 | 3% (43) | 11% | $225,054 |
| 2020 | 1,531 | 336 | 4% (60) | None | $120,505 |
| 2019 | 1,462 | 322 | 4% (53) | None | $109,546 |
| 2018 | 1,261 | 286 | 2% (26) | 11% | $116,001 |
| 2017 | 1,168 | 254 | 2% (26) | None | $111,049 |
| 2016 | 930 | 203 | 2% (18) | None | $98,869 |
| 2015 | 817 | 175 | 3% (24) | None | $87,525 |
| 2014 | 687 | 168 | 4% (29) | None | $71,786 |
| 2013 | 385 | 111 | 4% (14) | None | $25,362 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 28 drugs
| Xtandi | 20 | $192,731 | $9,637 |
| Myrbetriq | 89 | $57,935 | $651 |
| Gemtesa | 42 | $33,620 | $800 |
| Tamsulosin | 411 | $10,184 | $25 |
| Dutasteride | 145 | $9,665 | $67 |
| Finasteride | 332 | $5,975 | $18 |
| Tolterodine Tartrate Er | 13 | $4,448 | $342 |
| Potassium Citrate Er | 34 | $3,956 | $116 |
| Silodosin | 44 | $3,391 | $77 |
| Testosterone | 15 | $3,153 | $210 |
| Oxybutynin Chloride Er | 61 | $2,628 | $43 |
| Bicalutamide | 44 | $1,592 | $36 |
| Fesoterodine Fumarate Er | 17 | $770 | $45 |
| Testosterone Cypionate | 12 | $712 | $59 |
| Nitrofurantoin Mono-Macro | 19 | $578 | $30 |
| Ciprofloxacin | 62 | $575 | $9 |
| Alfuzosin Hcl Er | 18 | $571 | $32 |
| Cephalexin | 49 | $565 | $12 |
| Nitrofurantoin | 12 | $518 | $43 |
| Bethanechol Chloride | 11 | $518 | $47 |
| Pentoxifylline | 13 | $433 | $33 |
| Sulfamethoxazole-Trimethoprim | 21 | $355 | $17 |
| Allopurinol | 23 | $227 | $10 |
| Levofloxacin | 25 | $195 | $8 |
| Amoxicillin-Clavulanate Potass | 18 | $168 | $9 |
| Oxycodone-Acetaminophen | 14 | $156 | $11 |
| Tadalafil | 16 | $151 | $9 |
| Hydrocodone-Acetaminophen | 11 | $74 | $7 |
2022: 28 drugs
| Xtandi | 13 | $147,095 | $11,315 |
| Myrbetriq | 94 | $56,929 | $606 |
| Gemtesa | 22 | $15,793 | $718 |
| Toviaz | 14 | $9,468 | $676 |
| Tamsulosin | 427 | $8,178 | $19 |
| Finasteride | 375 | $7,238 | $19 |
| Potassium Citrate Er | 39 | $6,729 | $173 |
| Dutasteride | 81 | $6,235 | $77 |
| Silodosin | 36 | $2,943 | $82 |
| Tolterodine Tartrate Er | 16 | $2,891 | $181 |
| Oxybutynin Chloride Er | 40 | $1,805 | $45 |
| Testosterone | 12 | $1,443 | $120 |
| Bicalutamide | 25 | $1,296 | $52 |
| Bethanechol Chloride | 18 | $1,138 | $63 |
| Estradiol | 11 | $966 | $88 |
| Alfuzosin Hcl Er | 21 | $937 | $45 |
| Ciprofloxacin | 63 | $502 | $8 |
| Cephalexin | 35 | $485 | $14 |
| Nitrofurantoin Mono-Macro | 21 | $474 | $23 |
| Sulfamethoxazole-Trimethoprim | 47 | $441 | $9 |
| Pentoxifylline | 18 | $320 | $18 |
| Tadalafil | 20 | $309 | $15 |
| Allopurinol | 26 | $221 | $8 |
| Hydrocodone-Acetaminophen | 23 | $192 | $8 |
| Levofloxacin | 25 | $153 | $6 |
| Sildenafil Citrate | 11 | $130 | $12 |
| Amoxicillin-Clavulanate Potass | 13 | $127 | $10 |
| Naproxen | 13 | $9 | $1 |
2021: 24 drugs
| Myrbetriq | 86 | $50,474 | $587 |
| Toviaz | 36 | $23,398 | $650 |
| Tamsulosin | 482 | $8,810 | $18 |
| Gemtesa | 14 | $8,424 | $602 |
| Finasteride | 318 | $7,467 | $23 |
| Potassium Citrate Er | 31 | $5,088 | $164 |
| Dutasteride | 59 | $3,200 | $54 |
| Alfuzosin Hcl Er | 33 | $2,423 | $73 |
| Silodosin | 20 | $1,697 | $85 |
| Bethanechol Chloride | 19 | $1,599 | $84 |
| Oxybutynin Chloride Er | 41 | $1,482 | $36 |
| Nitrofurantoin Mono-Macro | 22 | $1,269 | $58 |
| Bicalutamide | 26 | $1,165 | $45 |
| Tadalafil | 19 | $972 | $51 |
| Celecoxib | 11 | $770 | $70 |
| Ciprofloxacin | 66 | $618 | $9 |
| Sulfamethoxazole-Trimethoprim | 41 | $454 | $11 |
| Cephalexin | 46 | $447 | $10 |
| Doxazosin Mesylate | 13 | $358 | $28 |
| Allopurinol | 23 | $314 | $14 |
| Pentoxifylline | 11 | $191 | $17 |
| Hydrocodone-Acetaminophen | 19 | $161 | $8 |
| Levofloxacin | 25 | $128 | $5 |
| Sildenafil Citrate | 11 | $34 | $3 |
2020: 22 drugs
| Myrbetriq | 86 | $47,653 | $554 |
| Toviaz | 42 | $20,666 | $492 |
| Finasteride | 354 | $7,266 | $21 |
| Tamsulosin | 431 | $7,119 | $17 |
| Potassium Citrate Er | 13 | $4,441 | $342 |
| Tadalafil | 17 | $3,431 | $202 |
| Dutasteride | 39 | $2,591 | $66 |
| Oxybutynin Chloride Er | 40 | $2,207 | $55 |
| Nitrofurantoin Mono-Macro | 29 | $2,131 | $73 |
| Alfuzosin Hcl Er | 40 | $1,665 | $42 |
| Bicalutamide | 29 | $1,248 | $43 |
| Solifenacin | 17 | $1,153 | $68 |
| Doxazosin Mesylate | 18 | $422 | $23 |
| Allopurinol | 25 | $401 | $16 |
| Sulfamethoxazole-Trimethoprim | 29 | $331 | $11 |
| Cephalexin | 43 | $321 | $7 |
| Nitrofurantoin | 11 | $294 | $27 |
| Ciprofloxacin | 44 | $264 | $6 |
| Hydrocodone-Acetaminophen | 38 | $260 | $7 |
| Levofloxacin | 13 | $132 | $10 |
| Sildenafil Citrate | 16 | $125 | $8 |
| Tramadol | 11 | $44 | $4 |
2019: 22 drugs
| Myrbetriq | 56 | $27,757 | $496 |
| Toviaz | 39 | $16,874 | $433 |
| Vesicare | 22 | $12,844 | $584 |
| Tamsulosin | 456 | $8,896 | $20 |
| Finasteride | 325 | $6,612 | $20 |
| Tadalafil | 13 | $3,469 | $267 |
| Tolterodine Tartrate Er | 21 | $1,761 | $84 |
| Oxybutynin Chloride Er | 24 | $1,408 | $59 |
| Dutasteride | 17 | $1,148 | $68 |
| Bicalutamide | 34 | $963 | $28 |
| Doxazosin Mesylate | 21 | $925 | $44 |
| Alfuzosin Hcl Er | 30 | $894 | $30 |
| Ciprofloxacin | 46 | $724 | $16 |
| Allopurinol | 25 | $518 | $21 |
| Nitrofurantoin Mono-Macro | 12 | $517 | $43 |
| Testosterone Cypionate | 16 | $481 | $30 |
| Cephalexin | 53 | $441 | $8 |
| Nitrofurantoin | 11 | $250 | $23 |
| Levofloxacin | 26 | $215 | $8 |
| Hydrocodone-Acetaminophen | 28 | $214 | $8 |
| Oxycodone | 16 | $114 | $7 |
| Sulfamethoxazole-Trimethoprim | 23 | $100 | $4 |
2018: 20 drugs
| Myrbetriq | 39 | $21,111 | $541 |
| Vesicare | 34 | $19,866 | $584 |
| Tamsulosin | 392 | $7,588 | $19 |
| Rapaflo | 17 | $6,477 | $381 |
| Finasteride | 305 | $5,434 | $18 |
| Toviaz | 11 | $3,523 | $320 |
| Potassium Citrate Er | 13 | $2,058 | $158 |
| Oxybutynin Chloride Er | 31 | $1,640 | $53 |
| Bicalutamide | 34 | $807 | $24 |
| Nitrofurantoin Mono-Macro | 13 | $794 | $61 |
| Dutasteride | 16 | $687 | $43 |
| Doxazosin Mesylate | 13 | $587 | $45 |
| Alfuzosin Hcl Er | 23 | $474 | $21 |
| Ciprofloxacin | 48 | $435 | $9 |
| Cephalexin | 50 | $398 | $8 |
| Allopurinol | 22 | $380 | $17 |
| Hydrocodone-Acetaminophen | 25 | $240 | $10 |
| Sulfamethoxazole-Trimethoprim | 25 | $136 | $5 |
| Amoxicillin-Clavulanate Potass | 13 | $133 | $10 |
| Levofloxacin | 16 | $131 | $8 |
2017: 20 drugs
| Vesicare | 56 | $23,674 | $423 |
| Myrbetriq | 41 | $20,506 | $500 |
| Androgel | 16 | $14,043 | $878 |
| Rapaflo | 40 | $12,899 | $322 |
| Tamsulosin | 286 | $6,779 | $24 |
| Cialis | 21 | $6,472 | $308 |
| Finasteride | 271 | $4,387 | $16 |
| Oxybutynin Chloride Er | 55 | $3,518 | $64 |
| Nitrofurantoin Mono-Macro | 19 | $1,026 | $54 |
| Dutasteride | 11 | $845 | $77 |
| Ciprofloxacin | 80 | $682 | $9 |
| Allopurinol | 20 | $424 | $21 |
| Bicalutamide | 12 | $301 | $25 |
| Amoxicillin-Clavulanate Potass | 24 | $288 | $12 |
| Cephalexin | 35 | $210 | $6 |
| Alfuzosin Hcl Er | 12 | $156 | $13 |
| Pantoprazole | 11 | $146 | $13 |
| Trimethoprim | 11 | $109 | $10 |
| Hydrocodone-Acetaminophen | 13 | $85 | $7 |
| Sulfamethoxazole-Trimethoprim | 11 | $77 | $7 |
2016: 14 drugs
| Myrbetriq | 42 | $19,733 | $470 |
| Vesicare | 40 | $19,286 | $482 |
| Rapaflo | 47 | $14,191 | $302 |
| Cialis | 25 | $8,375 | $335 |
| Enablex | 22 | $7,033 | $320 |
| Tamsulosin | 206 | $5,834 | $28 |
| Finasteride | 212 | $4,851 | $23 |
| Dutasteride | 20 | $3,342 | $167 |
| Oxybutynin Chloride Er | 39 | $1,770 | $45 |
| Nitrofurantoin Mono-Macro | 16 | $950 | $59 |
| Ciprofloxacin | 64 | $583 | $9 |
| Allopurinol | 13 | $331 | $25 |
| Levofloxacin | 12 | $168 | $14 |
| Cephalexin | 12 | $60 | $5 |
2015: 18 drugs
| Rapaflo | 63 | $14,553 | $231 |
| Vesicare | 31 | $12,382 | $399 |
| Myrbetriq | 16 | $9,450 | $591 |
| Avodart | 37 | $7,921 | $214 |
| Casodex | 12 | $6,327 | $527 |
| Tamsulosin | 169 | $6,313 | $37 |
| Cialis | 16 | $4,667 | $292 |
| Finasteride | 156 | $2,634 | $17 |
| Nitrofurantoin Mono-Macro | 32 | $1,462 | $46 |
| Oxybutynin Chloride Er | 24 | $1,378 | $57 |
| Nystatin-Triamcinolone | 11 | $1,377 | $125 |
| Allopurinol | 19 | $501 | $26 |
| Ciprofloxacin | 47 | $333 | $7 |
| Sulfamethoxazole-Trimethoprim | 31 | $280 | $9 |
| Cephalexin | 14 | $149 | $11 |
| Hydrocodone-Acetaminophen | 15 | $141 | $9 |
| Amoxicillin-Clavulanate Potass | 11 | $137 | $12 |
| Hydrochlorothiazide | 17 | $117 | $7 |
2014: 14 drugs
| Vesicare | 35 | $13,100 | $374 |
| Rapaflo | 43 | $8,718 | $203 |
| Avodart | 39 | $8,676 | $222 |
| Casodex | 11 | $5,817 | $529 |
| Tamsulosin | 125 | $3,825 | $31 |
| Enablex | 13 | $2,594 | $200 |
| Finasteride | 85 | $1,949 | $23 |
| Nitrofurantoin Mono-Macro | 20 | $1,578 | $79 |
| Oxybutynin Chloride Er | 19 | $1,392 | $73 |
| Bicalutamide | 15 | $595 | $40 |
| Ciprofloxacin | 67 | $538 | $8 |
| Sulfamethoxazole-Trimethoprim | 27 | $253 | $9 |
| Allopurinol | 17 | $207 | $12 |
| Hydrocodone-Acetaminophen | 26 | $195 | $7 |
2013: 10 drugs
| Vesicare | 13 | $5,373 | $413 |
| Rapaflo | 18 | $4,982 | $277 |
| Enablex | 18 | $3,024 | $168 |
| Finasteride | 65 | $2,292 | $35 |
| Tamsulosin | 80 | $2,017 | $25 |
| Bicalutamide | 12 | $373 | $31 |
| Amox Tr-Potassium Clavulanate | 12 | $228 | $19 |
| Ciprofloxacin | 37 | $227 | $6 |
| Sulfamethoxazole-Trimethoprim | 21 | $149 | $7 |
| Hydrocodone-Acetaminophen | 13 | $97 | $7 |
Money from drug and device companies
$1,840 in 2025
| 2025 | 14 | 70 | None | $1,840 |
| 2024 | 14 | 43 | None | $1,215 |
| 2023 | 17 | 48 | None | $1,301 |
| 2022 | 16 | 55 | None | $1,305 |
| 2021 | 13 | 31 | None | $592 |
| 2020 | 12 | 27 | None | $566 |
| 2019 | 16 | 68 | None | $1,123 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Sumitomo Pharma America | Gemtesa | $1,037 | 34 payments
|
| Accord Healthcare | Camcevi | $144 | 7 payments
|
| Abbvie | Botox | $135 | 6 payments
|
| Novartis Pharmaceuticals | Pluvicto | $105 | 4 payments
|
| Verity Pharmaceuticals | Tlando | $63 | 3 payments
|
| Coloplast | Luja Coude | $56 | 3 payments
|
See all 70 published payments
| Sumitomo Pharma America | Meals · 2025-12-19 | Gemtesa | $32 |
| Ferring Pharmaceuticals | Meals · 2025-12-16 | Adstiladrin | $21 |
| Sumitomo Pharma America | Meals · 2025-12-12 | Gemtesa | $40 |
| Abbvie | Meals · 2025-12-11 | Lupron Depot | $14 |
| Abbvie | Meals · 2025-12-09 | Botox | $26 |
| Sumitomo Pharma America | Meals · 2025-11-11 | Gemtesa | $22 |
| Coloplast | Meals · 2025-11-11 | Luja Coude | $22 |
| Accord Healthcare | Meals · 2025-11-10 | Camcevi | $16 |
| Sumitomo Pharma America | Meals · 2025-11-02 | Gemtesa | $45 |
| Janssen Biotech | Meals · 2025-10-28 | Erleada | $31 |
| Sumitomo Pharma America | Meals · 2025-10-24 | Gemtesa | $38 |
| Sumitomo Pharma America | Meals · 2025-10-16 | Gemtesa | $36 |
| Novartis Pharmaceuticals | Meals · 2025-10-16 | Pluvicto | $19 |
| Sumitomo Pharma America | Meals · 2025-10-09 | Gemtesa | $36 |
| Verity Pharmaceuticals | Meals · 2025-10-07 | Tlando | $24 |
| Accord Healthcare | Meals · 2025-10-01 | Camcevi | $24 |
| Sumitomo Pharma America | Meals · 2025-09-25 | Gemtesa | $40 |
| Sumitomo Pharma America | Meals · 2025-09-19 | Gemtesa | $28 |
| Verity Pharmaceuticals | Meals · 2025-09-09 | Tlando | $16 |
| Abbvie | Meals · 2025-09-08 | Lupron Depot | $21 |
| Sumitomo Pharma America | Meals · 2025-09-05 | Gemtesa | $38 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-02 | Nubeqa | $22 |
| Accord Healthcare | Meals · 2025-08-29 | Camcevi | $6 |
| Novartis Pharmaceuticals | Meals · 2025-08-14 | Pluvicto | $19 |
| Sumitomo Pharma America | Meals · 2025-08-13 | Gemtesa | $38 |
| Verity Pharmaceuticals | Meals · 2025-08-13 | Tlando | $23 |
| Astellas Pharma US | Meals · 2025-08-12 | Xtandi | $25 |
| Sumitomo Pharma America | Meals · 2025-07-31 | Gemtesa | $35 |
| Antares Pharma | Meals · 2025-07-24 | Xyosted | $27 |
| Sumitomo Pharma America | Meals · 2025-07-22 | Gemtesa | $14 |
| Accord Healthcare | Meals · 2025-07-17 | Camcevi | $26 |
| Sumitomo Pharma America | Meals · 2025-07-09 | Gemtesa | $36 |
| Progenics Pharmaceuticals | Meals · 2025-07-09 | Pylarify | $21 |
| Sumitomo Pharma America | Meals · 2025-06-29 | Gemtesa | $10 |
| Coloplast | Meals · 2025-06-24 | Luja Coude | $17 |
| Sumitomo Pharma America | Meals · 2025-06-19 | Gemtesa | $35 |
| Sumitomo Pharma America | Meals · 2025-06-09 | Gemtesa | $16 |
| Novartis Pharmaceuticals | Meals · 2025-06-05 | Pluvicto | $32 |
| Accord Healthcare | Meals · 2025-06-04 | Camcevi | $22 |
| Sumitomo Pharma America | Meals · 2025-05-28 | Gemtesa | $39 |
| Abbvie | Meals · 2025-05-21 | Botox | $25 |
| Sumitomo Pharma America | Meals · 2025-05-16 | Gemtesa | $17 |
| Pfizer | Meals · 2025-05-13 | Xtandi | $22 |
| Sumitomo Pharma America | Meals · 2025-05-09 | Gemtesa | $31 |
| Sumitomo Pharma America | Meals · 2025-05-02 | Gemtesa | $41 |
| Sumitomo Pharma America | Meals · 2025-04-25 | Gemtesa | $41 |
| Novartis Pharmaceuticals | Meals · 2025-04-22 | Pluvicto | $34 |
| Abbvie | Meals · 2025-04-18 | Botox | $24 |
| Coloplast | Meals · 2025-04-15 | Luja Coude | $17 |
| Progenics Pharmaceuticals | Meals · 2025-04-14 | Pylarify | $15 |
| Sumitomo Pharma America | Meals · 2025-04-07 | Gemtesa | $39 |
| Accord Healthcare | Meals · 2025-04-03 | Camcevi | $24 |
| Sumitomo Pharma America | Meals · 2025-03-26 | Gemtesa | $26 |
| Abbvie | Meals · 2025-03-24 | Botox | $23 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-03-24 | Nubeqa | $27 |
| Sumitomo Pharma America | Meals · 2025-03-19 | Gemtesa | $42 |
| Janssen Biotech | Meals · 2025-03-18 | Erleada | $25 |
| Telix Pharmaceuticals | Meals · 2025-03-14 | Illuccix | $26 |
| Sumitomo Pharma America | Meals · 2025-03-12 | Gemtesa | $40 |
| Telix Pharmaceuticals | Meals · 2025-03-02 | Illuccix | $20 |
| Sumitomo Pharma America | Education · 2025-02-28 | Gemtesa | $5 |
| Sumitomo Pharma America | Meals · 2025-02-27 | Gemtesa | $26 |
| Accord Healthcare | Meals · 2025-02-19 | Camcevi | $27 |
| Sumitomo Pharma America | Meals · 2025-02-14 | Gemtesa | $36 |
| Astellas Pharma US | Meals · 2025-02-11 | Xtandi | $20 |
| Sumitomo Pharma America | Meals · 2025-02-06 | Gemtesa | $23 |
| Sumitomo Pharma America | Meals · 2025-02-06 | Gemtesa | $18 |
| Sumitomo Pharma America | Meals · 2025-01-29 | Gemtesa | $28 |
| Sumitomo Pharma America | Meals · 2025-01-14 | Gemtesa | $9 |
| Sumitomo Pharma America | Meals · 2025-01-09 | Gemtesa | $37 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,215
| Astellas Pharma US | Xtandi | $354 | 11 payments
|
| Sumitomo Pharma America | Gemtesa | $287 | 9 payments
|
| Blue Earth Diagnostics | Posluma | $108 | 4 payments
|
| Janssen Biotech | Erleada | $70 | 3 payments
|
| Dendreon Pharmaceuticals | Provenge | $66 | 2 payments
|
| Immunitybio | Anktiva | $63 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $61 | 3 payments
|
| Coloplast | Luja Coude | $57 | 2 payments
|
| Abbvie | Lupron Depot | $38 | 2 payments
|
| Olympus America | Itind System | $30 | 1 payment
|
| Laborie Medical Technologies | Optilume Bph Drug Coated Balloon Catheter | $26 | 1 payment
|
| Novartis Pharmaceuticals | Pluvicto | $20 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $19 | 1 payment
|
| Antares Pharma | Xyosted | $15 | 1 payment
|
2023: $1,301
| Astellas Pharma US | Myrbetriq | $301 | 16 payments
|
| Sumitomo Pharma America | Gemtesa | $267 | 9 payments
|
| Dendreon Pharmaceuticals | Provenge | $138 | 4 payments
|
| Edap Technomed | None | $125 | 1 payment
|
| Amgen | Xgeva | $103 | 3 payments
|
| Janssen Biotech | Erleada | $87 | 3 payments
|
| Ethicon US | Vistaseal | $38 | 1 payment
|
| Antares Pharma | Nocdurna | $38 | 2 payments
|
| Myriad Genetic Laboratories | Prolaris | $31 | 1 payment
|
| Tolmar | Jatenzo | $28 | 1 payment
|
| Coloplast | Speedicath | $28 | 1 payment
|
| Endo Pharmaceuticals | Aveed | $25 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $21 | 1 payment
|
| Progenics Pharmaceuticals | Pylarify | $20 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $20 | 1 payment
|
| Abbvie | Lupron Depot | $17 | 1 payment
|
| Supernus Pharmaceuticals | Xyosted | $16 | 1 payment
|
2022: $1,305
| Astellas Pharma US | Myrbetriq | $428 | 19 payments
|
| Urovant Sciences | Gemtesa | $275 | 9 payments
|
| Antares Pharma | Nocdurna | $157 | 7 payments
|
| Dendreon Pharmaceuticals | Provenge | $63 | 2 payments
|
| Amgen | Xgeva | $58 | 2 payments
|
| Accord Healthcare | Camcevi | $54 | 3 payments
|
| Hollister | Vapro Plus Pocket | $41 | 2 payments
|
| Janssen Biotech | Erleada | $40 | 2 payments
|
| Allergan | Botox | $34 | 2 payments
|
| UroGen Pharma | None | $27 | 1 payment
|
| Abbvie | Lupron Depot | $27 | 1 payment
|
| Progenics Pharmaceuticals | Pylarify | $22 | 1 payment
|
| Myriad Genetic Laboratories | Brac Cdx | $21 | 1 payment
|
| 180 Medical | Gentlecath | $21 | 1 payment
|
| Myovant Sciences | Orgovyx | $20 | 1 payment
|
| Blue Earth Diagnostics | Axumin | $17 | 1 payment
|
2021: $592
| Astellas Pharma US | Xtandi | $203 | 13 payments
|
| Urovant Sciences | Gemtesa | $81 | 3 payments
|
| Janssen Biotech | Erleada | $60 | 3 payments
|
| 180 Medical | Gentlecath | $46 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $38 | 2 payments
|
| Amgen | Xgeva | $28 | 1 payment
|
| AbbVie | Lupron Depot | $23 | 1 payment
|
| TOLMAR Pharmaceuticals | Eligard | $23 | 1 payment
|
| TherapeuticsMD | Imvexxy | $21 | 1 payment
|
| Urogen Pharma | Jelmyto | $21 | 1 payment
|
| Antares Pharma | Xyosted | $20 | 1 payment
|
| Axonics | Axonics R-Snm System | $17 | 1 payment
|
| Allergan | Botox | $12 | 1 payment
|
2020: $566
| Astellas Pharma US | Xtandi | $275 | 11 payments
|
| Coloplast | Speedicath | $48 | 3 payments
|
| Janssen Biotech | Erleada | $47 | 3 payments
|
| 180 Medical | Speedicath | $40 | 2 payments
|
| Amgen | Prolia | $26 | 1 payment
|
| AbbVie | Lupron Depot | $24 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $22 | 1 payment
|
| Dentsply Ih | Lofric | $18 | 1 payment
|
| TOLMAR Pharmaceuticals | Eligard | $17 | 1 payment
|
| Antares Pharma | Otrexup | $17 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $17 | 1 payment
|
| Photocure | Cysview | $15 | 1 payment
|
2019: $1,123
| Astellas Pharma US | Myrbetriq | $218 | 14 payments
|
| Janssen Biotech | Erleada | $164 | 20 payments
|
| Dendreon Pharmaceuticals | Provenge | $162 | 6 payments
|
| Amgen | Prolia | $161 | 6 payments
|
| Coloplast | Speedicath | $60 | 4 payments
|
| Pfizer | Xtandi | $56 | 3 payments
|
| AbbVie | Lupron Depot | $47 | 2 payments
|
| TOLMAR Pharmaceuticals | Eligard | $43 | 2 payments
|
| TherapeuticsMD | Imvexxy | $41 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $39 | 2 payments
|
| Antares Pharma | Xyosted | $34 | 2 payments
|
| Endo Pharmaceuticals | Xiaflex | $24 | 1 payment
|
| Ferring Pharmaceuticals | Nocdurna | $20 | 1 payment
|
| PROCEPT BioRobotics | Aquabeam Robotic System | $19 | 1 payment
|
| Photocure | Cysview | $18 | 1 payment
|
| Zyla Life Sciences | Zorvolex | $16 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1497726095
- Licence
- CA C 54669California C54669: Current · expires 2028-07-31
- Trained
- Saint Louis University School of Medicine, 1998
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X)
- Mailing address
- 2460 Samaritan Dr, San Jose, CA, 95124
- NPI first listed
- 2006-01-31
- NPI last updated
- 2016-09-07
This is when the NPI record was last certified, not a medical board exam.